National Cancer Institute; Notice of Closed Meetings, 6205 [2020-02068]
Download as PDF
<![CDATA[
Federal Register / Vol. 85, No. 23 / Tuesday, February 4, 2020 / Notices
including biosimilars and
interchangeable products, and to
discuss the important impact these
products have on public health. This
includes:
• U.S. Biosimilar Markets and FDA
Approval Process;
• Enforcement Activities by FDA and
FTC;
• The Benefits of Competition; and
• Improving Stakeholder
Engagement: Education and Access.
FDA and FTC also encourage
comments from stakeholders and the
public relating to steps FDA and FTC
can take to facilitate a competitive
market for biological products.
khammond on DSKJM1Z7X2PROD with NOTICES
III. Participating in the Public
Workshop
The FDA Conference Center at the
White Oak location is a Federal facility
with security procedures and limited
seating. Attendance will be free and on
a first-come, first-served basis. An
agenda for the workshop and any other
background materials will be made
available 5 days before the workshop at
https://www.fda.gov/drugs/news-eventshuman-drugs/public-workshop-fdaftcworkshop-competitive-marketplacebiosimilars-03092020-03092020. If you
need special accommodations because
of a disability, please contact Sandra
Benton (see FOR FURTHER INFORMATION
CONTACT) at least 7 days before the
workshop.
Registration and Requests for Open
Public Workshop Speaker Slots. For
those interested in participating as an
Open Public Workshop speaker, please
register at https://www.eventbrite.com/
e/86931096249 as ‘‘In-person Open
Public Workshop presenter.’’ Open
Public Workshop registrations are due
by February 24, 2020; however, if time
is available, you may sign up as an
Open Public Workshop speaker the day
of the meeting. Time and space are
limited and available on a first-come,
first-served basis. Open Public
Workshop speakers may be assigned no
more than 5 minutes for their
presentation and will deliver oral
testimony only (no accompanying slide
deck).
We will do our best to accommodate
requests to make public comments.
Individuals and organizations with
common interests are urged to
consolidate or coordinate their
presentations and request time for a
joint presentation. All requests to make
oral presentations must be received by
February 24, 2020. No commercial or
promotional material will be permitted
to be presented or distributed at the
public workshop.
VerDate Sep<11>2014
17:48 Feb 03, 2020
Jkt 250001
In-Person Attendance: For those who
would like to attend in person, but who
are not participating in the Open Public
Workshop, please register at https://
www.eventbrite.com/e/86931096249 as
‘‘In-person attendee—no participation.’’
You may choose not to register;
however, seating is limited, and space
will be available on a first-come, firstserved basis.
Persons attending FDA’s workshops
are advised that FDA is not responsible
for providing access to electrical outlets.
Streaming Webcast of the Public
Workshop: For those unable to attend in
person, FDA will provide a live webcast
of the workshop. To join the workshop
via the webcast, please go to https://
www.fda.gov/drugs/news-eventshuman-drugs/public-workshop-fdaftcworkshop-competitive-marketplacebiosimilars-03092020-03092020 for the
webcast address. Please register at
https://www.eventbrite.com/e/
86931096249 as ‘‘online (webcast
only).’’
Media: Please register at https://
www.eventbrite.com/e/86931096249 as
‘‘Media’’ by March 4, 2020.
Transcripts: Please be advised that
when a transcript of the public
workshop is available, it will be
accessible at https://
www.regulations.gov. It may be viewed
at the Dockets Management Staff (see
ADDRESSES).
Dated: January 29, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020–02101 Filed 2–3–20; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of
meetings of the Board of Scientific
Counselors for Basic Sciences National
Cancer Institute.
The meetings will be closed to the
public as indicated below in accordance
with the provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
National Cancer Institute, including
consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
Fmt 4703
Sfmt 4703
Name of Committee: Board of Scientific
Counselors for Basic Sciences; National
Cancer Institute.
Date: March 9, 2020.
Time: 9:00 a.m. to 4:30 p.m.
Agenda: To review and evaluate personnel
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health, Porter
Neuroscience Research Center, 35 Convent
Drive, Building 35A, Bethesda, MD 20892.
Contact Person: Mehrdad M. Tondravi,
Ph.D., Chief Institute Review Office, NCI,
National Institutes of Health, 9609 Medical
Center Drive, ROOM 2W–464 MSC 9711,
Rockville, MD 20852, 240–276–5664,
tondravim@mail.nih.gov.
Name of Committee: Board of Scientific
Counselors for Clinical Sciences and
Epidemiology; National Cancer Institute.
Date: March 10, 2020.
Time: 9:00 a.m. to 2:30 p.m.
Agenda: To review and evaluate personnel
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health, Porter
Neuroscience Research Center, 35 Convent
Drive, Building 35A, Bethesda, MD 20892.
Contact Person: Brian E. Wojcik, Ph.D.,
Institute Review Office, Office of The
Director, National Cancer Institute, 6116
Executive Blvd., Room 2201, Bethesda, MD
20892, 301–496–7628, wojcikb@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: January 29, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4140–01–P
National Cancer Institute; Notice of
Closed Meetings
Frm 00065
constitute a clearly unwarranted
invasion of personal privacy.
[FR Doc. 2020–02068 Filed 2–3–20; 8:45 am]
National Institutes of Health
PO 00000
6205
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Library of Medicine; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
E:\FR\FM\04FEN1.SGM
04FEN1
]]>Agencies
[Federal Register Volume 85, Number 23 (Tuesday, February 4, 2020)]
[Notices]
[Page 6205]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-02068]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of meetings of the Board of Scientific
Counselors for Basic Sciences National Cancer Institute.
The meetings will be closed to the public as indicated below in
accordance with the provisions set forth in section 552b(c)(6), Title 5
U.S.C., as amended for the review, discussion, and evaluation of
individual intramural programs and projects conducted by the National
Cancer Institute, including consideration of personnel qualifications
and performance, and the competence of individual investigators, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: Board of Scientific Counselors for Basic
Sciences; National Cancer Institute.
Date: March 9, 2020.
Time: 9:00 a.m. to 4:30 p.m.
Agenda: To review and evaluate personnel qualifications and
performance, and competence of individual investigators.
Place: National Institutes of Health, Porter Neuroscience
Research Center, 35 Convent Drive, Building 35A, Bethesda, MD 20892.
Contact Person: Mehrdad M. Tondravi, Ph.D., Chief Institute
Review Office, NCI, National Institutes of Health, 9609 Medical
Center Drive, ROOM 2W-464 MSC 9711, Rockville, MD 20852, 240-276-
5664, [email protected].
Name of Committee: Board of Scientific Counselors for Clinical
Sciences and Epidemiology; National Cancer Institute.
Date: March 10, 2020.
Time: 9:00 a.m. to 2:30 p.m.
Agenda: To review and evaluate personnel qualifications and
performance, and competence of individual investigators.
Place: National Institutes of Health, Porter Neuroscience
Research Center, 35 Convent Drive, Building 35A, Bethesda, MD 20892.
Contact Person: Brian E. Wojcik, Ph.D., Institute Review Office,
Office of The Director, National Cancer Institute, 6116 Executive
Blvd., Room 2201, Bethesda, MD 20892, 301-496-7628,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: January 29, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-02068 Filed 2-3-20; 8:45 am]
BILLING CODE 4140-01-P
